9T14 Rec'd PCT/PT9 0 2 DEC 2004

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER SSL0093-1

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/516704

CONCERNING A FILING UNDER 35 U.S.C. 3/1								
INTERNATIONAL APPLICATION NO. PCT/FR03/01685		INTERNATIONAL FILING DATE 5 June 2003	PRIORITY DATE CLAIMED 7 June 2002					
TITLE OF INVENTION: PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF								
APPLIC	CANT(S) FOR DO/EO/US	20, THERET REPARENTED THE REAL	EUTIC USE THEREOF					
BONO, Francoise; BOSCH, Michael; DOS SANTOS, Victor; HERBERT, Jean-Marc; NISATO, Dino; TONNERRE, Bernard; WAGNON, Jean								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other								
	ormation:							
1. 🔯	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2. 🔲	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3. 🔀	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay							
	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and							
	39(1)).							
4. 🛛	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest							
	claimed priority date.							
5. 🔀								
	a. is transmitted herewith (required only if not transmitted by the International Bureau).							
	b. A has been transmitted by the	International Bureau.						
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6. 🔀	An English language translation of th	e International Application.						
7. 🔀	Amendments to the claims of the Inte	rnational Application under PCT Article	19 (35 U.S.C. 371 (c)(3))					
	a. are transmitted herewith (re-	quired only if not transmitted by the Inter	national Bureau).					
	b. have been transmitted by the	e International Bureau.						
	c. have not been made; howev	er, the time limit for making such amend	ments has NOT expired.					
	d. A have not been made and wil	I not be made.	-					
8. 🔲	An English language translation of th	e amendments to the claims under PCT	Article 19 (35 U.S.C. 371 (c)(3)).					
9 🛛	An executed oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	An English language translation of the annexes to the International Preliminary Examination Report under PCT							
	Article 36 (35 U.S.C. 371(c)(5)).							
	, , , , , ,							
Items, 11. to 16. below concern document(s) or information included:								
11. 🗹	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.						
12. 🛛		ng. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is					
	included.							
12 🏹	A CIDST realiminant amandment							
13. 🛚	A FIRST preliminary amendment.							
	A SECOND or SUBSEQUENT preli	minary amendment						
لسا	A BLECK OF SCHOLL OF THE PICK	minary amendment.						
14. 🔲	A substitute specification.							
	•							
15. 🔲	A change of power of attorney and/or	address letter.						
16. 🛚	Other items or information:							
	<u>Citation of References</u> <u>Information Disclosure Statement by</u>	Applicant (Form PTO-1440)						
	intormation Disclosure Statement by	Applicant (LOIM LLO-177)						

U.S. APPLICATION NO. (if kn	own, see 37 CFR 1.5)	INTERN	ATIONAL APPLICATION NO.		A.	TTORNEY'S DOCKET	NUMBER	
10/516	5704	PCT/FR03/01685				SSL0093-1		
17. The following fees are submitted: CALCULATIONS PTO USE ONL								SE ONLY
BASIC NATIONAL FEE (37 CFR 1. 492 (a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO								
International prel	International preliminary examination fee (37 CFR 1.482) not paid to							
USPTO but Inter	l							
International preliminary examination fee (37 CFR 1.482) not paid to								
USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO								
but all claims did	but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$750.00							
International prel	liminary examination	n fee (37 CFR 1.482) paid to	USPTO				
and all claims sat			ticle 33(1)-(4)		L			
			ROPRIATE BASIC		= \$	950.00		
			declaration later than	[]20 []30	\$			
months from the earli	NUMBER FILI		NUMBER EXTRA	RATE	╁			
Total claims		-20 =	NUMBER EXTRA	x \$18.00	\$	90.00	<u> </u>	
Independent claims	*	$\frac{-20-}{2-3}$	0	x \$88.00	\$	0.00	┪	
MULTIPLE DEPEN				+ \$300.00	\$	0.00		
			TAL OF ABOVE CA			1,040.00		
Reduction of 1/2 for	filing by small entity	y, if ap	plicable. Verified Sma	all Entity Statement	\$			
must also be filed (N	ote 37 CFR 1.9, 1.2	7, 1.2	3).	SUBTOTAL :	┸	_		
	= \$ \$	1,040.00						
Processing fee of \$130.00 for furnishing the English translation later than [] 20[] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).								
TOTAL NATIONAL FEE =						1,040.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be								
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + TOTAL FEES ENCLOSED = \$ 1,040.00								
			TOTALLE	ES ENCEOSED -	Ť	Amount to l	pe \$	
						refunde		
						Charge	ed \$	
a. A check in the amount of \$ to cover the above fees is enclosed.								
h M Disease shares man Damasit Assessment No. 10 0001. In the surround of \$1.040.00 as secure than the								
b. Please charge my Deposit Account No. 19-0091 in the amount of \$ 1,040.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. Main The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPOND	DENCE TO:			SIGN	ATU	Lly on	12	DATE
Patent Department			07546			V		
Sanofi-Synthelabo Inc.			27546			Dupont		
9 Great Valley Parkway	25 440							
P.O. Box 3026 Malvern, PA 19355	P.O. Box 3026 27,438 Malvern, PA 19355 REGISTRATION NUMBER							
Facsimile: (610) 889-8799 (610) 889-6338 TELEPHONE NUMBER								
i .				IELE	เกทบ	IND INCINIDEK		

Application of:

BONO, Francoise BOSCH, Michael DOS SANTOS, Victor HERBERT, Jean-Marc NISATO, Dino

TONNERRE, Bernard WAGNON, Jean

Docket No.:

SSL0093-1

Filing Under 35 U.S.C. § 371

Filed As a U.S. National Phase Application of

International Application No. PCT/FR03/01685

Filed 05 June 2003

FOR: PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR

PREPARATION AND THERAPEUTIC USE THEREOF

CERTIFICATE UNDER 37 C.F.R. 1.10

Signature					
Genedine Delee					
Alexandria, VA 22313-1450					
P.O. Box 1450					
Commissioner for Patents					
Mail Stop PCT					
date indicated above, and is addressed to:					
Postal Service "Express Mail Post Office to Addressee" Service on the					
I hereby certify that this paper is being deposited with the United States					
and of Bopooli.					
Date of Deposit: December 2, 2004					
Express Mail Label No.: EV 591423795 US					

ENGLISH TRANSLATION OF INTERNATIONAL PATENT APPLICATION PCT/FR03/01685

filed on 05 June 2003

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.:	EV 591423795 US			
Date of Deposit:	ecember 2, 2004			

I hereby certify that the attached English Translation is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Signature